<?xml version="1.0" ?><ns2:com.thomson.ls.soa.stack.soaservices.service.contract.soap.v4.search.SearchOutput xmlns:ns2="local" id="be423766-8ee9-48e2-b4a8-2e2d9b4e22eb" dataset="sourcesCorporatePublication" time="37"><serviceExecutionTime>0</serviceExecutionTime><lastDatasetUpdate>2019-02-16T00:12:36Z</lastDatasetUpdate><PagedResults total="149" firstRow="1" lastRow="140"><Result pos="1"><Field name="sourceId" type="string">1419372</Field><Field name="corporatePublicationTitle" type="string">Pain Therapeutics</Field><Field name="corporatePublicationType" type="string">Securities and Exchange Commission Form 8K</Field><Field name="corporatePublicationDatePublication" type="datetime">2013-05-10T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Pain Therapeutics Inc</Field></Result><Result pos="2"><Field name="sourceId" type="string">781965</Field><Field name="corporatePublicationTitle" type="string">Pain Therapeutics website</Field><Field name="corporatePublicationType" type="string">Company World Wide Web site</Field><Field name="corporatePublicationDatePublication" type="datetime">2007-04-10T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Pain Therapeutics Inc</Field></Result><Result pos="3"><Field name="sourceId" type="string">505745</Field><Field name="corporatePublicationTitle" type="string">Form 10K: Pain Therapeutics Inc</Field><Field name="corporatePublicationType" type="string">Securities and Exchange Commission Form 10-K</Field><Field name="corporatePublicationDatePublication" type="datetime">2003-03-17T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Pain Therapeutics Inc</Field></Result><Result pos="4"><Field name="sourceId" type="string">1885960</Field><Field name="corporatePublicationTitle" type="string">Pain Therapeutics Inc: Form 8K</Field><Field name="corporatePublicationType" type="string">Securities and Exchange Commission Form 8K</Field><Field name="corporatePublicationDatePublication" type="datetime">2016-12-08T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Pain Therapeutics Inc</Field></Result><Result pos="5"><Field name="sourceId" type="string">360311</Field><Field name="corporatePublicationTitle" type="string">Pain Therapeutics Inc S-1</Field><Field name="corporatePublicationType" type="string">Securities and Exchange Commission Form S-1</Field><Field name="corporatePublicationDatePublication" type="datetime">2000-03-14T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Pain Therapeutics Inc</Field></Result><Result pos="6"><Field name="sourceId" type="string">1309196</Field><Field name="corporatePublicationTitle" type="string">Pain Therapeutics: Clinical pipeline</Field><Field name="corporatePublicationType" type="string">Company World Wide Web site</Field><Field name="corporatePublicationDatePublication" type="datetime">2012-07-18T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Pain Therapeutics Inc</Field></Result><Result pos="7"><Field name="sourceId" type="string">1608038</Field><Field name="corporatePublicationTitle" type="string">Pain Therapeutics: Form 8-K</Field><Field name="corporatePublicationType" type="string">Securities and Exchange Commission Form 8K</Field><Field name="corporatePublicationDatePublication" type="datetime">2014-10-29T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Pain Therapeutics Inc</Field></Result><Result pos="8"><Field name="sourceId" type="string">1242093</Field><Field name="corporatePublicationTitle" type="string">Pain Therapeutics Company Worldwide Website</Field><Field name="corporatePublicationType" type="string">Company World Wide Web site</Field><Field name="corporatePublicationDatePublication" type="datetime">2011-11-22T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Pain Therapeutics Inc</Field></Result><Result pos="9"><Field name="sourceId" type="string">781991</Field><Field name="corporatePublicationTitle" type="string">Form 10-K: Pain Therapeutics</Field><Field name="corporatePublicationType" type="string">Securities and Exchange Commission Form 10-K</Field><Field name="corporatePublicationDatePublication" type="datetime">2006-02-24T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Pain Therapeutics Inc</Field></Result><Result pos="10"><Field name="sourceId" type="string">781989</Field><Field name="corporatePublicationTitle" type="string">Pain Therapeutics 10-K: 2006</Field><Field name="corporatePublicationType" type="string">Securities and Exchange Commission Form 10-K</Field><Field name="corporatePublicationDatePublication" type="datetime">2007-02-26T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Pain Therapeutics Inc</Field></Result><Result pos="11"><Field name="sourceId" type="string">1268079</Field><Field name="corporatePublicationTitle" type="string">The American Academy of Pain Medicine: AAPM Facts and Figures on Pain</Field><Field name="corporatePublicationType" type="string">Company Presentation</Field><Field name="corporatePublicationDatePublication" type="datetime">2012-12-31T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">The American Academy of Pain Medicine</Field></Result><Result pos="12"><Field name="sourceId" type="string">505767</Field><Field name="corporatePublicationTitle" type="string">Annual Report 2002: Pain Therapeutics, Inc</Field><Field name="corporatePublicationType" type="string">Annual Report</Field><Field name="corporatePublicationDatePublication" type="datetime">2003-01-01T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Pain Therapeutics Inc</Field></Result><Result pos="13"><Field name="sourceId" type="string">922396</Field><Field name="corporatePublicationTitle" type="string">Form 10-K 2007 - Pain Therapeutics Inc</Field><Field name="corporatePublicationType" type="string">Securities and Exchange Commission Form 10-K</Field><Field name="corporatePublicationDatePublication" type="datetime">2008-02-13T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Pain Therapeutics Inc</Field></Result><Result pos="14"><Field name="sourceId" type="string">476541</Field><Field name="corporatePublicationTitle" type="string">Pain Therapeutics Inc - 2003 conference call</Field><Field name="corporatePublicationType" type="string">Company Presentation</Field><Field name="corporatePublicationDatePublication" type="datetime">2003-01-16T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Pain Therapeutics Inc</Field></Result><Result pos="15"><Field name="sourceId" type="string">781993</Field><Field name="corporatePublicationTitle" type="string">Form 10-k: Pain Therapeutics Inc</Field><Field name="corporatePublicationType" type="string">Securities and Exchange Commission Form 10-K</Field><Field name="corporatePublicationDatePublication" type="datetime">2004-03-12T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Pain Therapeutics Inc</Field></Result><Result pos="16"><Field name="sourceId" type="string">1742991</Field><Field name="corporatePublicationTitle" type="string">Form 10-K 2015 - Pain Therapeutics Inc</Field><Field name="corporatePublicationType" type="string">Securities and Exchange Commission Form 10-K</Field><Field name="corporatePublicationDatePublication" type="datetime">2016-03-03T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Pain Therapeutics Inc</Field></Result><Result pos="17"><Field name="sourceId" type="string">625372</Field><Field name="corporatePublicationTitle" type="string">Pain Therapeutics Inc: Annual report 2004</Field><Field name="corporatePublicationType" type="string">Annual Report</Field><Field name="corporatePublicationDatePublication" type="datetime">2005-02-16T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Pain Therapeutics Inc</Field></Result><Result pos="18"><Field name="sourceId" type="string">922398</Field><Field name="corporatePublicationTitle" type="string">Annual Report 2007 - Pain Therapeutics Inc</Field><Field name="corporatePublicationType" type="string">Annual Report</Field><Field name="corporatePublicationDatePublication" type="datetime">2008-03-31T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Pain Therapeutics Inc</Field></Result><Result pos="19"><Field name="sourceId" type="string">2011331</Field><Field name="corporatePublicationTitle" type="string">Form 10-K 2017 - Pain Therapeutics Inc</Field><Field name="corporatePublicationType" type="string">Securities and Exchange Commission Form 10-K</Field><Field name="corporatePublicationDatePublication" type="datetime">2018-02-06T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Pain Therapeutics Inc</Field></Result><Result pos="20"><Field name="sourceId" type="string">982143</Field><Field name="corporatePublicationTitle" type="string">Pain Therapeutics: pipeline, factor IX replacement</Field><Field name="corporatePublicationType" type="string">Company World Wide Web site</Field><Field name="corporatePublicationDatePublication" type="datetime">2009-02-06T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Pain Therapeutics Inc</Field></Result><Result pos="21"><Field name="sourceId" type="string">1907552</Field><Field name="corporatePublicationTitle" type="string">Form 10-K 2016 - Pain Therapeutics Inc</Field><Field name="corporatePublicationType" type="string">Securities and Exchange Commission Form 10-K</Field><Field name="corporatePublicationDatePublication" type="datetime">2017-03-07T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Pain Therapeutics Inc</Field></Result><Result pos="22"><Field name="sourceId" type="string">1012948</Field><Field name="corporatePublicationTitle" type="string">Pain Therapeutics Inc: Annual Report for the year ended 31 December 2008</Field><Field name="corporatePublicationType" type="string">Annual Report</Field><Field name="corporatePublicationDatePublication" type="datetime">2009-03-31T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Pain Therapeutics Inc</Field></Result><Result pos="23"><Field name="sourceId" type="string">1012944</Field><Field name="corporatePublicationTitle" type="string">Pain Therapeutics Inc: Form 10-K for the year ended 31 December 2008</Field><Field name="corporatePublicationType" type="string">Securities and Exchange Commission Form 10-K</Field><Field name="corporatePublicationDatePublication" type="datetime">2009-02-13T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Pain Therapeutics Inc</Field></Result><Result pos="24"><Field name="sourceId" type="string">625373</Field><Field name="corporatePublicationTitle" type="string">Pain Therapeutics Inc: Form 10K for the year ended 31 December 2004</Field><Field name="corporatePublicationType" type="string">Securities and Exchange Commission Form 10-K</Field><Field name="corporatePublicationDatePublication" type="datetime">2005-02-16T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Pain Therapeutics Inc</Field></Result><Result pos="25"><Field name="sourceId" type="string">1260586</Field><Field name="corporatePublicationTitle" type="string">International Association for the Study of Pain: IASP Taxonomy</Field><Field name="corporatePublicationType" type="string">Company Presentation</Field><Field name="corporatePublicationDatePublication" type="datetime">2011-12-31T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">International Association for the Study of Pain</Field></Result><Result pos="26"><Field name="sourceId" type="string">979172</Field><Field name="corporatePublicationTitle" type="string">Pain therapy</Field><Field name="corporatePublicationType" type="string">Company World Wide Web site</Field><Field name="corporatePublicationDatePublication" type="datetime">2009-01-26T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Grunenthal GmbH</Field></Result><Result pos="27"><Field name="sourceId" type="string">1738619</Field><Field name="corporatePublicationTitle" type="string">Essential Pain Pharmacology</Field><Field name="corporatePublicationType" type="string">Company Publication</Field><Field name="corporatePublicationDatePublication" type="datetime">2016-02-29T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Cambridge Medicine</Field></Result><Result pos="28"><Field name="sourceId" type="string">501059</Field><Field name="corporatePublicationTitle" type="string">Products - Pain - Migraine - SRSS-023</Field><Field name="corporatePublicationType" type="string">Company World Wide Web site</Field><Field name="corporatePublicationDatePublication" type="datetime">2003-08-01T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Sirus Pharmaceuticals Ltd</Field></Result><Result pos="29"><Field name="sourceId" type="string">784427</Field><Field name="corporatePublicationTitle" type="string">MediVas: Applications: Pain Management</Field><Field name="corporatePublicationType" type="string">Company World Wide Web site</Field><Field name="corporatePublicationDatePublication" type="datetime">2007-04-16T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">MediVas LLC</Field></Result><Result pos="30"><Field name="sourceId" type="string">1091181</Field><Field name="corporatePublicationTitle" type="string">NOLabs Ab: Diabetic pain relief</Field><Field name="corporatePublicationType" type="string">Company World Wide Web site</Field><Field name="corporatePublicationDatePublication" type="datetime">2009-01-27T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">NOLabs Ab</Field></Result><Result pos="31"><Field name="sourceId" type="string">480162</Field><Field name="corporatePublicationTitle" type="string">Ardent: Moderate-to-severe pain</Field><Field name="corporatePublicationType" type="string">Company World Wide Web site</Field><Field name="corporatePublicationDatePublication" type="datetime">2003-02-27T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Ardent Pharmaceuticals Inc</Field></Result><Result pos="32"><Field name="sourceId" type="string">907883</Field><Field name="corporatePublicationTitle" type="string">M6G – post-operative pain</Field><Field name="corporatePublicationType" type="string">Company World Wide Web site</Field><Field name="corporatePublicationDatePublication" type="datetime">2008-05-20T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">CeNeS Pharmaceuticals Inc</Field></Result><Result pos="33"><Field name="sourceId" type="string">970073</Field><Field name="corporatePublicationTitle" type="string">company website pain research pipeline</Field><Field name="corporatePublicationType" type="string">Company World Wide Web site</Field><Field name="corporatePublicationDatePublication" type="datetime">2008-12-10T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Abbott Laboratories</Field></Result><Result pos="34"><Field name="sourceId" type="string">500889</Field><Field name="corporatePublicationTitle" type="string">Products - Pain - Neuropathic - SRSC-355</Field><Field name="corporatePublicationType" type="string">Company World Wide Web site</Field><Field name="corporatePublicationDatePublication" type="datetime">2003-08-01T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Sirus Pharmaceuticals Ltd</Field></Result><Result pos="35"><Field name="sourceId" type="string">455033</Field><Field name="corporatePublicationTitle" type="string">Sedation and Pain Relief</Field><Field name="corporatePublicationType" type="string">Company World Wide Web site</Field><Field name="corporatePublicationDatePublication" type="datetime">2002-06-18T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Orion Pharma</Field></Result><Result pos="36"><Field name="sourceId" type="string">500887</Field><Field name="corporatePublicationTitle" type="string">Products - Pain - Breakthrough - SRSS-001</Field><Field name="corporatePublicationType" type="string">Company World Wide Web site</Field><Field name="corporatePublicationDatePublication" type="datetime">2003-08-01T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Sirus Pharmaceuticals Ltd</Field></Result><Result pos="37"><Field name="sourceId" type="string">1063841</Field><Field name="corporatePublicationTitle" type="string">Pain in Europe: A report</Field><Field name="corporatePublicationType" type="string">Company Publication</Field><Field name="corporatePublicationDatePublication" type="datetime">2004-10-31T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">PainEurope.com</Field></Result><Result pos="38"><Field name="sourceId" type="string">501058</Field><Field name="corporatePublicationTitle" type="string">Products - Pain - Acute - SRSS-016</Field><Field name="corporatePublicationType" type="string">Company World Wide Web site</Field><Field name="corporatePublicationDatePublication" type="datetime">2003-08-01T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Sirus Pharmaceuticals Ltd</Field></Result><Result pos="39"><Field name="sourceId" type="string">1930623</Field><Field name="corporatePublicationTitle" type="string">Rapid, Reliable Pain Relief</Field><Field name="corporatePublicationType" type="string">Company Presentation</Field><Field name="corporatePublicationDatePublication" type="datetime">2015-11-04T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Klaria Pharma Holding Ab</Field></Result><Result pos="40"><Field name="sourceId" type="string">1072598</Field><Field name="corporatePublicationTitle" type="string">Pain Relief / Analgesia - Healthcare Professionals</Field><Field name="corporatePublicationType" type="string">Company World Wide Web site</Field><Field name="corporatePublicationDatePublication" type="datetime">2010-02-02T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Medical Developments International Ltd</Field></Result><Result pos="41"><Field name="sourceId" type="string">876237</Field><Field name="corporatePublicationTitle" type="string">Product Pipeline: TC-2696 pain</Field><Field name="corporatePublicationType" type="string">Company World Wide Web site</Field><Field name="corporatePublicationDatePublication" type="datetime">2008-02-13T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Targacept Inc</Field></Result><Result pos="42"><Field name="sourceId" type="string">590572</Field><Field name="corporatePublicationTitle" type="string">Home - Programs - Neuropathic pain</Field><Field name="corporatePublicationType" type="string">Company World Wide Web site</Field><Field name="corporatePublicationDatePublication" type="datetime">2005-03-18T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">ACADIA Pharmaceuticals Inc</Field></Result><Result pos="43"><Field name="sourceId" type="string">968756</Field><Field name="corporatePublicationTitle" type="string">Abbott pain research pipeline</Field><Field name="corporatePublicationType" type="string">Company World Wide Web site</Field><Field name="corporatePublicationDatePublication" type="datetime">2008-12-05T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Abbott Laboratories</Field></Result><Result pos="44"><Field name="sourceId" type="string">1565018</Field><Field name="corporatePublicationTitle" type="string">Company communication - Pain research</Field><Field name="corporatePublicationType" type="string">Company Communication</Field><Field name="corporatePublicationDatePublication" type="datetime">2014-05-30T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">AbbVie Inc</Field></Result><Result pos="45"><Field name="sourceId" type="string">406336</Field><Field name="corporatePublicationTitle" type="string">Corporate profile: Topical pain therapy for the treatment chronic pain</Field><Field name="corporatePublicationType" type="string">Company World Wide Web site</Field><Field name="corporatePublicationDatePublication" type="datetime">2001-04-19T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Epitome Pharmaceuticals Ltd</Field></Result><Result pos="46"><Field name="sourceId" type="string">612174</Field><Field name="corporatePublicationTitle" type="string">Pain and inflammation therapeutics - a non-narcotic agent for treating acute and chronic pain</Field><Field name="corporatePublicationType" type="string">Company World Wide Web site</Field><Field name="corporatePublicationDatePublication" type="datetime">2005-07-12T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Microbia Inc</Field></Result><Result pos="47"><Field name="sourceId" type="string">500881</Field><Field name="corporatePublicationTitle" type="string">Drug discovery: Therapeutic Focus, Chronic pain</Field><Field name="corporatePublicationType" type="string">Company World Wide Web site</Field><Field name="corporatePublicationDatePublication" type="datetime">2003-08-13T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Amedis Pharmaceuticals Ltd</Field></Result><Result pos="48"><Field name="sourceId" type="string">1161303</Field><Field name="corporatePublicationTitle" type="string">Cancer pain treatment, "Wandyuro  ®  Patch "Gets Approval</Field><Field name="corporatePublicationType" type="string">Company World Wide Web site</Field><Field name="corporatePublicationDatePublication" type="datetime">2011-01-14T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Janssen Pharmaceutical Co., Ltd.</Field></Result><Result pos="49"><Field name="sourceId" type="string">1363123</Field><Field name="corporatePublicationTitle" type="string">Technology offer: Adjuvant for improved regional pain management</Field><Field name="corporatePublicationType" type="string">Company World Wide Web site</Field><Field name="corporatePublicationDatePublication" type="datetime">2013-01-25T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Bayerische Patentallianz GmbH</Field></Result><Result pos="50"><Field name="sourceId" type="string">207756</Field><Field name="corporatePublicationTitle" type="string">Product Profile: DepoMorphine post-surgical acute pain management</Field><Field name="corporatePublicationType" type="string">Company Communication</Field><Field name="corporatePublicationDatePublication" type="datetime">1996-05-16T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">DepoTech Corp</Field></Result><Result pos="51"><Field name="sourceId" type="string">462649</Field><Field name="corporatePublicationTitle" type="string">Making waves with solutions in pain management</Field><Field name="corporatePublicationType" type="string">Annual Report</Field><Field name="corporatePublicationDatePublication" type="datetime">2002-03-31T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">International Wex Technologies Inc</Field></Result><Result pos="52"><Field name="sourceId" type="string">1012109</Field><Field name="corporatePublicationTitle" type="string">Prolonged release of Lidocaine for pain relief</Field><Field name="corporatePublicationType" type="string">Company World Wide Web site</Field><Field name="corporatePublicationDatePublication" type="datetime">2009-05-22T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Uppsala University</Field></Result><Result pos="53"><Field name="sourceId" type="string">453915</Field><Field name="corporatePublicationTitle" type="string">Enhance.L: Pain relief for OBGYN procedures</Field><Field name="corporatePublicationType" type="string">Company World Wide Web site</Field><Field name="corporatePublicationDatePublication" type="datetime">2002-06-07T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Enhance Pharmaceuticals Inc</Field></Result><Result pos="54"><Field name="sourceId" type="string">962385</Field><Field name="corporatePublicationTitle" type="string">Phosphagenics Ltd: Delivering Pain Drugs Topically and Systemically</Field><Field name="corporatePublicationType" type="string">Company Presentation</Field><Field name="corporatePublicationDatePublication" type="datetime">2008-10-07T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Phosphagenics Ltd</Field></Result><Result pos="55"><Field name="sourceId" type="string">1559893</Field><Field name="corporatePublicationTitle" type="string">Pain indication update for ALO-02 and Remoxy</Field><Field name="corporatePublicationType" type="string">Company Communication</Field><Field name="corporatePublicationDatePublication" type="datetime">2014-05-20T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Pfizer Inc</Field></Result><Result pos="56"><Field name="sourceId" type="string">867257</Field><Field name="corporatePublicationTitle" type="string">Enhance pain management using endothelin receptor antagonists</Field><Field name="corporatePublicationType" type="string">Company Publication</Field><Field name="corporatePublicationDatePublication" type="datetime">2003-01-23T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">University of Illinois</Field></Result><Result pos="57"><Field name="sourceId" type="string">1313897</Field><Field name="corporatePublicationTitle" type="string">Assessment and Management of Acute Pain (6th Edition)</Field><Field name="corporatePublicationType" type="string">Company World Wide Web site</Field><Field name="corporatePublicationDatePublication" type="datetime">2008-03-31T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Institute for Clinical Systems Improvement</Field></Result><Result pos="58"><Field name="sourceId" type="string">1204544</Field><Field name="corporatePublicationTitle" type="string">Xefo Rapid (lornoxicam) – for fast pain relief</Field><Field name="corporatePublicationType" type="string">Company World Wide Web site</Field><Field name="corporatePublicationDatePublication" type="datetime">2011-12-31T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string"></Field></Result><Result pos="59"><Field name="sourceId" type="string">1273841</Field><Field name="corporatePublicationTitle" type="string">Therapeutic Class Review - Pain - Short-actign Opioids</Field><Field name="corporatePublicationType" type="string">Company World Wide Web site</Field><Field name="corporatePublicationDatePublication" type="datetime">2010-04-30T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string"></Field></Result><Result pos="60"><Field name="sourceId" type="string">1211590</Field><Field name="corporatePublicationTitle" type="string">TLI-0326: Oral Treatment of Diabetic Neuropathy Pain</Field><Field name="corporatePublicationType" type="string">Company Publication</Field><Field name="corporatePublicationDatePublication" type="datetime">2011-07-25T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Trinity Laboratories Inc</Field></Result><Result pos="61"><Field name="sourceId" type="string">1275346</Field><Field name="corporatePublicationTitle" type="string">Therapeutic Class Review Pain - Long-Acting Opioids: Embeda</Field><Field name="corporatePublicationType" type="string">Company World Wide Web site</Field><Field name="corporatePublicationDatePublication" type="datetime">2010-04-30T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string"></Field></Result><Result pos="62"><Field name="sourceId" type="string">435316</Field><Field name="corporatePublicationTitle" type="string">Neurology CEDD disease area strategy/ Pain</Field><Field name="corporatePublicationType" type="string">Company Brochure</Field><Field name="corporatePublicationDatePublication" type="datetime">2001-11-01T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">GlaxoSmithKline plc</Field></Result><Result pos="63"><Field name="sourceId" type="string">1037064</Field><Field name="corporatePublicationTitle" type="string">Abstral-treatment of breakthough cancer pain</Field><Field name="corporatePublicationType" type="string">Company World Wide Web site</Field><Field name="corporatePublicationDatePublication" type="datetime">2009-08-26T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Orexo</Field></Result><Result pos="64"><Field name="sourceId" type="string">851078</Field><Field name="corporatePublicationTitle" type="string">CNS: Pain Program Fact Sheet: PLX-5568</Field><Field name="corporatePublicationType" type="string">Company World Wide Web site</Field><Field name="corporatePublicationDatePublication" type="datetime">2007-10-31T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Plexxikon Inc</Field></Result><Result pos="65"><Field name="sourceId" type="string">792923</Field><Field name="corporatePublicationTitle" type="string">Targacept: Product pipeline: TC-6499 pain</Field><Field name="corporatePublicationType" type="string">Company World Wide Web site</Field><Field name="corporatePublicationDatePublication" type="datetime">2007-05-10T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Targacept Inc</Field></Result><Result pos="66"><Field name="sourceId" type="string">1471098</Field><Field name="corporatePublicationTitle" type="string">Breakthrough Therapies for Neuropathic Pain and Neurological Disorders</Field><Field name="corporatePublicationType" type="string">Company Publication</Field><Field name="corporatePublicationDatePublication" type="datetime">2011-04-04T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">University of Colorado Technology Transfer Office</Field></Result><Result pos="67"><Field name="sourceId" type="string">1274832</Field><Field name="corporatePublicationTitle" type="string">Fentanyl patches (Durogesic) for chronic pain</Field><Field name="corporatePublicationType" type="string">Company World Wide Web site</Field><Field name="corporatePublicationDatePublication" type="datetime">2006-06-30T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Australian Government Department of Health and Ageing</Field></Result><Result pos="68"><Field name="sourceId" type="string">1263741</Field><Field name="corporatePublicationTitle" type="string">Xen2174-A new class of pain therapeutics</Field><Field name="corporatePublicationType" type="string">Company Publication</Field><Field name="corporatePublicationDatePublication" type="datetime">2011-02-28T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Xenome Ltd</Field></Result><Result pos="69"><Field name="sourceId" type="string">531000</Field><Field name="corporatePublicationTitle" type="string">Biosciences Division: Pain/analgesia: Basic research</Field><Field name="corporatePublicationType" type="string">Company World Wide Web site</Field><Field name="corporatePublicationDatePublication" type="datetime">2004-04-06T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">SRI International</Field></Result><Result pos="70"><Field name="sourceId" type="string">474063</Field><Field name="corporatePublicationTitle" type="string">Acute and Chronic Pain: RI-624</Field><Field name="corporatePublicationType" type="string">Company World Wide Web site</Field><Field name="corporatePublicationDatePublication" type="datetime">2002-12-13T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Rinat Neuroscience Corp</Field></Result><Result pos="71"><Field name="sourceId" type="string">1256481</Field><Field name="corporatePublicationTitle" type="string">A pilot study on the effect of ARA290 on pain and pain responses and retinal edema in patients with diabetes mellitus and neuropathic pain; EudraCT Number: 2010-021518-4</Field><Field name="corporatePublicationType" type="string">Company Publication</Field><Field name="corporatePublicationDatePublication" type="datetime">2011-02-05T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Araim Pharmaceuticals Inc</Field></Result><Result pos="72"><Field name="sourceId" type="string">1461524</Field><Field name="corporatePublicationTitle" type="string">A Phase II Novel Therapeutic Approach for Treating Pain Approach for Treating Pain, Multiple Multiple Sclerosis, or Drug Addiction</Field><Field name="corporatePublicationType" type="string">Company Presentation</Field><Field name="corporatePublicationDatePublication" type="datetime">2013-12-31T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string"></Field></Result><Result pos="73"><Field name="sourceId" type="string">831368</Field><Field name="corporatePublicationTitle" type="string">BioCentury, The Bernstein Report Emerging Company Profile Solace: Comfort in (Pain) Research</Field><Field name="corporatePublicationType" type="string">Company World Wide Web site</Field><Field name="corporatePublicationDatePublication" type="datetime">2007-07-09T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Solace Pharmaceuticals</Field></Result><Result pos="74"><Field name="sourceId" type="string">505307</Field><Field name="corporatePublicationTitle" type="string">Drug development pipeline - vanilloid receptor 1 antagonists (pain), Purdue Pharma</Field><Field name="corporatePublicationType" type="string">Company Communication</Field><Field name="corporatePublicationDatePublication" type="datetime">2003-09-16T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Purdue Pharma LP</Field></Result><Result pos="75"><Field name="sourceId" type="string">665802</Field><Field name="corporatePublicationTitle" type="string">KD7040 - topical pain product. Inducible nitric oxide synthase (iNOS) inhibitor 2Q2006</Field><Field name="corporatePublicationType" type="string">Company Newsletter</Field><Field name="corporatePublicationDatePublication" type="datetime">2006-05-04T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Kalypsys Inc</Field></Result><Result pos="76"><Field name="sourceId" type="string">1025895</Field><Field name="corporatePublicationTitle" type="string">Glial Cells—A New Target for Chronic Pain Treatment</Field><Field name="corporatePublicationType" type="string">Company Publication</Field><Field name="corporatePublicationDatePublication" type="datetime">2009-12-31T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Avigen Inc</Field></Result><Result pos="77"><Field name="sourceId" type="string">1268281</Field><Field name="corporatePublicationTitle" type="string">Relieving Pain in America: A Blueprint for Transforming Prevention, Care, Education, and Research</Field><Field name="corporatePublicationType" type="string">Company Presentation</Field><Field name="corporatePublicationDatePublication" type="datetime">2011-12-31T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Institute of Medicine of the National Academies</Field></Result><Result pos="78"><Field name="sourceId" type="string">1274333</Field><Field name="corporatePublicationTitle" type="string">KINDOLOR - A new molecular entity for treating chronic pain and cancer</Field><Field name="corporatePublicationType" type="string">Company Presentation</Field><Field name="corporatePublicationDatePublication" type="datetime">2012-03-26T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Lohocla Research Corp</Field></Result><Result pos="79"><Field name="sourceId" type="string">1096851</Field><Field name="corporatePublicationTitle" type="string">Designing systemically active galanin analogs for the treatment of epilepsy and pain</Field><Field name="corporatePublicationType" type="string">Company Presentation</Field><Field name="corporatePublicationDatePublication" type="datetime">2010-02-01T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">NeuroAdjuvants Inc</Field></Result><Result pos="80"><Field name="sourceId" type="string">277409</Field><Field name="corporatePublicationTitle" type="string">DepoTech Corp product profile - DepoMorphine - post-surgical acute pain management</Field><Field name="corporatePublicationType" type="string">Company Brochure</Field><Field name="corporatePublicationDatePublication" type="datetime">1997-02-11T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">DepoTech Corp</Field></Result><Result pos="81"><Field name="sourceId" type="string">1609911</Field><Field name="corporatePublicationTitle" type="string">GDC-0276 and Other Selective Inhibitors of NaV1.7 for the Treatment of Pain</Field><Field name="corporatePublicationType" type="string">Company World Wide Web site</Field><Field name="corporatePublicationDatePublication" type="datetime">2014-11-07T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Xenon Pharmaceuticals Inc</Field></Result><Result pos="82"><Field name="sourceId" type="string">460461</Field><Field name="corporatePublicationTitle" type="string">Information for shareholders on the progress of the Canadian cancer pain trial</Field><Field name="corporatePublicationType" type="string">Company Publication</Field><Field name="corporatePublicationDatePublication" type="datetime">2002-03-27T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">International Wex Technologies Inc</Field></Result><Result pos="83"><Field name="sourceId" type="string">494391</Field><Field name="corporatePublicationTitle" type="string">A new option for cancer patients: Advanced pain management with transdermal buprenorphine (Transtec)</Field><Field name="corporatePublicationType" type="string">Company Presentation</Field><Field name="corporatePublicationDatePublication" type="datetime">2003-06-21T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Gruenenthal GmbH</Field></Result><Result pos="84"><Field name="sourceId" type="string">755450</Field><Field name="corporatePublicationTitle" type="string">Horizon Therapeutics: Novel therapeis for mild-to-moderate pain</Field><Field name="corporatePublicationType" type="string">Company World Wide Web site</Field><Field name="corporatePublicationDatePublication" type="datetime">2007-01-05T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Horizon Therapeutics Inc</Field></Result><Result pos="85"><Field name="sourceId" type="string">1272464</Field><Field name="corporatePublicationTitle" type="string">Technology offer: Use of beta-adrenergic receptor agonists for treatment of neuropathic pain</Field><Field name="corporatePublicationType" type="string">Company World Wide Web site</Field><Field name="corporatePublicationDatePublication" type="datetime">2012-03-16T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Conectus Alsace</Field></Result><Result pos="86"><Field name="sourceId" type="string">1310203</Field><Field name="corporatePublicationTitle" type="string">UP-069: Prevention and treatment of pain in diabetes mellitus patients</Field><Field name="corporatePublicationType" type="string">Company Publication</Field><Field name="corporatePublicationDatePublication" type="datetime">2012-07-23T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">University of Heidelberg</Field></Result><Result pos="87"><Field name="sourceId" type="string">643947</Field><Field name="corporatePublicationTitle" type="string">Spinifex: Developing novel solutions for the treatment of pain</Field><Field name="corporatePublicationType" type="string">Company World Wide Web site</Field><Field name="corporatePublicationDatePublication" type="datetime">2006-01-06T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Spinifex Pharmaceuticals Pty Ltd</Field></Result><Result pos="88"><Field name="sourceId" type="string">1312531</Field><Field name="corporatePublicationTitle" type="string">Xefo as an adjunct agent in post-operative pain</Field><Field name="corporatePublicationType" type="string">Company World Wide Web site</Field><Field name="corporatePublicationDatePublication" type="datetime">2012-08-01T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Takeda Pharmaceutical Co Ltd</Field></Result><Result pos="89"><Field name="sourceId" type="string">920427</Field><Field name="corporatePublicationTitle" type="string">Drug development update: TRPV3 receptor antagonists (pain/osteoarthritis), Glenmark</Field><Field name="corporatePublicationType" type="string">Company Communication</Field><Field name="corporatePublicationDatePublication" type="datetime">2008-06-26T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Glenmark Pharmaceuticals Ltd</Field></Result><Result pos="90"><Field name="sourceId" type="string">1363116</Field><Field name="corporatePublicationTitle" type="string">FMP website; Technology offer TO 08-00085: Peptide for improved pain management</Field><Field name="corporatePublicationType" type="string">Company World Wide Web site</Field><Field name="corporatePublicationDatePublication" type="datetime">2013-01-25T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Leibniz-Institut fur Molekulare Pharmakologie</Field></Result><Result pos="91"><Field name="sourceId" type="string">1209378</Field><Field name="corporatePublicationTitle" type="string">A new paradigm in pain treatment- Project APN601 (DREAM)</Field><Field name="corporatePublicationType" type="string">Company Publication</Field><Field name="corporatePublicationDatePublication" type="datetime">2011-07-20T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Apeiron Biologics GmbH</Field></Result><Result pos="92"><Field name="sourceId" type="string">1208016</Field><Field name="corporatePublicationTitle" type="string">A new paradigm in pain treatment-Project APN601 (DREAM)</Field><Field name="corporatePublicationType" type="string">Company Publication</Field><Field name="corporatePublicationDatePublication" type="datetime">2011-07-18T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Apeiron Biologics GmbH</Field></Result><Result pos="93"><Field name="sourceId" type="string">1041160</Field><Field name="corporatePublicationTitle" type="string">Archimedes Announces US Filing of NasalFent®for the treatment of Breakthrough Cancer Pain</Field><Field name="corporatePublicationType" type="string">Company World Wide Web site</Field><Field name="corporatePublicationDatePublication" type="datetime">2009-09-11T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Archimedes Pharma</Field></Result><Result pos="94"><Field name="sourceId" type="string">923876</Field><Field name="corporatePublicationTitle" type="string">Anesiva: Annual report 2007 "Changing the face of pain"</Field><Field name="corporatePublicationType" type="string">Annual Report</Field><Field name="corporatePublicationDatePublication" type="datetime">2008-03-14T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Anesiva Inc</Field></Result><Result pos="95"><Field name="sourceId" type="string">1215629</Field><Field name="corporatePublicationTitle" type="string">[Drug development update]: therapeutic program (inflammation/autoimmune diseases/pain), SEEK</Field><Field name="corporatePublicationType" type="string">Company Communication</Field><Field name="corporatePublicationDatePublication" type="datetime">2011-08-12T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">SEEK</Field></Result><Result pos="96"><Field name="sourceId" type="string">675243</Field><Field name="corporatePublicationTitle" type="string">Anesiva Inc: Annual report 2005 (labelled as "Corgentech") - "Building a Pain Management Franchise"</Field><Field name="corporatePublicationType" type="string">Annual Report</Field><Field name="corporatePublicationDatePublication" type="datetime">2006-03-30T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Anesiva Inc</Field></Result><Result pos="97"><Field name="sourceId" type="string">441966</Field><Field name="corporatePublicationTitle" type="string">ZeP-3: a synthetic drug of natural origin for chronic pain</Field><Field name="corporatePublicationType" type="string">Company World Wide Web site</Field><Field name="corporatePublicationDatePublication" type="datetime">2002-03-04T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Shulov Institute for Science Ltd</Field></Result><Result pos="98"><Field name="sourceId" type="string">955145</Field><Field name="corporatePublicationTitle" type="string">Clinical Observation on the Effect of Kanglaite Injection in the Treatment of Cancerous Pain</Field><Field name="corporatePublicationType" type="string">Company Publication</Field><Field name="corporatePublicationDatePublication" type="datetime">2008-10-13T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Luo, Yao, Wang</Field></Result><Result pos="99"><Field name="sourceId" type="string">1382419</Field><Field name="corporatePublicationTitle" type="string">EP4 Receptor Antagonist for Chronic Inflammatory Pain; Worldwide Partnering Opportunity</Field><Field name="corporatePublicationType" type="string">Company Publication</Field><Field name="corporatePublicationDatePublication" type="datetime">2013-12-31T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">RaQualia Pharma Inc</Field></Result><Result pos="100"><Field name="sourceId" type="string">1072323</Field><Field name="corporatePublicationTitle" type="string">NOVEL SODIUM CHANNEL BLOCKERS FOR THE TREATMENT OF NEUROPATHIC PAIN</Field><Field name="corporatePublicationType" type="string">Company Publication</Field><Field name="corporatePublicationDatePublication" type="datetime">2010-02-02T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Neurosciences Victoria Ltd</Field></Result><Result pos="101"><Field name="sourceId" type="string">1441157</Field><Field name="corporatePublicationTitle" type="string">NEO6860: Vanilloid receptor antagonists for the treatment of osteoarthritis, neuropathic and visceral pain</Field><Field name="corporatePublicationType" type="string">Company Publication</Field><Field name="corporatePublicationDatePublication" type="datetime">2013-04-18T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">NEOMED Institute</Field></Result><Result pos="102"><Field name="sourceId" type="string">180514</Field><Field name="corporatePublicationTitle" type="string">Oral analgesic combination for patients with moderate to severe pain.</Field><Field name="corporatePublicationType" type="string">Company Brochure</Field><Field name="corporatePublicationDatePublication" type="datetime">1995-03-01T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">British Technology Group Ltd</Field></Result><Result pos="103"><Field name="sourceId" type="string">666890</Field><Field name="corporatePublicationTitle" type="string">Sufentanil TDS: A Licensing Opportunity for the Chronic Pain Market</Field><Field name="corporatePublicationType" type="string">Company Presentation</Field><Field name="corporatePublicationDatePublication" type="datetime">2006-01-31T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Labtec GmbH</Field></Result><Result pos="104"><Field name="sourceId" type="string">398273</Field><Field name="corporatePublicationTitle" type="string">Drug development pipeline: ion channel modulators for epilepsy and pain therapy</Field><Field name="corporatePublicationType" type="string">Company Communication</Field><Field name="corporatePublicationDatePublication" type="datetime">2001-02-08T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">ICAgen Inc</Field></Result><Result pos="105"><Field name="sourceId" type="string">944118</Field><Field name="corporatePublicationTitle" type="string">Rapinyl /Abstral - treatment of acute pain in cancer patients</Field><Field name="corporatePublicationType" type="string">Company World Wide Web site</Field><Field name="corporatePublicationDatePublication" type="datetime">2008-09-17T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Orexo AB</Field></Result><Result pos="106"><Field name="sourceId" type="string">1249034</Field><Field name="corporatePublicationTitle" type="string">Lipopharma: LPA181 in Spinal Cord Injury &amp;amp; neuropathic pain</Field><Field name="corporatePublicationType" type="string">Company World Wide Web site</Field><Field name="corporatePublicationDatePublication" type="datetime">2011-12-15T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Lipopharma Therapeutics SL</Field></Result><Result pos="107"><Field name="sourceId" type="string">1709890</Field><Field name="corporatePublicationTitle" type="string">FDA Orphan Drug Designations and Approvals: baclofen (Gablofen); Treatment of complex regional pain syndrome</Field><Field name="corporatePublicationType" type="string">Company World Wide Web site</Field><Field name="corporatePublicationDatePublication" type="datetime">2015-10-28T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Food and Drug Administration</Field></Result><Result pos="108"><Field name="sourceId" type="string">1709074</Field><Field name="corporatePublicationTitle" type="string">FDA Orphan Drug Designations and Approvals: baclofen (Gablofen); Treatment of complex regional pain syndrome</Field><Field name="corporatePublicationType" type="string">Company World Wide Web site</Field><Field name="corporatePublicationDatePublication" type="datetime">2015-10-28T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Food and Drug Administration</Field></Result><Result pos="109"><Field name="sourceId" type="string">536728</Field><Field name="corporatePublicationTitle" type="string">Microbia Inc R&amp;amp;D Pipeline: Pain and Inflammation Therapeutics</Field><Field name="corporatePublicationType" type="string">Company World Wide Web site</Field><Field name="corporatePublicationDatePublication" type="datetime">2004-05-05T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Microbia Inc</Field></Result><Result pos="110"><Field name="sourceId" type="string">789119</Field><Field name="corporatePublicationTitle" type="string">Antibe Therapeutics Inc: Product Platform and Pipeline: ATB-346: Acute and Chronic Joint Pain</Field><Field name="corporatePublicationType" type="string">Company World Wide Web site</Field><Field name="corporatePublicationDatePublication" type="datetime">2007-05-01T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Antibe Therapeutics Inc</Field></Result><Result pos="111"><Field name="sourceId" type="string">1273451</Field><Field name="corporatePublicationTitle" type="string">Novel oramucosal (Abstral, Effentora) and nasal (Instanyl) fentanyl for breakthrough pain associated with cancer</Field><Field name="corporatePublicationType" type="string">Company World Wide Web site</Field><Field name="corporatePublicationDatePublication" type="datetime">2009-09-30T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">NHS North East Treatment Advisory Group</Field></Result><Result pos="112"><Field name="sourceId" type="string">1031773</Field><Field name="corporatePublicationTitle" type="string">Pegylation Of Interleukin-10 To Enhance Delivery To The Central Nervous System And Therapeutic Efficacy For Neuropathic Pain</Field><Field name="corporatePublicationType" type="string">Company Presentation</Field><Field name="corporatePublicationDatePublication" type="datetime">2007-11-08T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">University of Colorado System</Field></Result><Result pos="113"><Field name="sourceId" type="string">424770</Field><Field name="corporatePublicationTitle" type="string">AstraZeneca research: cardiovascular, central nervous system, gastrointestinal, infection, oncology, pain control &amp;amp; anaesthesia and respiratory</Field><Field name="corporatePublicationType" type="string">Company World Wide Web site</Field><Field name="corporatePublicationDatePublication" type="datetime">2001-10-09T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">AstraZeneca plc</Field></Result><Result pos="114"><Field name="sourceId" type="string">1192276</Field><Field name="corporatePublicationTitle" type="string">Extended-release multivesicular liposome bupivacaine (EXPAREL) is superior to placebo for post-hemorrhoidectomy pain reduction</Field><Field name="corporatePublicationType" type="string">Company Presentation</Field><Field name="corporatePublicationDatePublication" type="datetime">2011-05-17T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Pacira Pharmaceuticals Inc</Field></Result><Result pos="115"><Field name="sourceId" type="string">1774357</Field><Field name="corporatePublicationTitle" type="string">FDA Orphan Drug Designations and Approvals: hydromorphone hydrochloride (intrathecal infusion);  Treatment of complex regional pain syndrome</Field><Field name="corporatePublicationType" type="string">Company World Wide Web site</Field><Field name="corporatePublicationDatePublication" type="datetime">2016-06-16T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Food and Drug Administration</Field></Result><Result pos="116"><Field name="sourceId" type="string">1193896</Field><Field name="corporatePublicationTitle" type="string">The American College of Obstetricians and Gynecologists (ACOG): Pain Management of Endometriosis - Conservative approach is first-line treatment</Field><Field name="corporatePublicationType" type="string">Company World Wide Web site</Field><Field name="corporatePublicationDatePublication" type="datetime">2010-06-22T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">http://www.acog.org/from_home/publications/press_releases/nr06-22-10-3.cfm</Field></Result><Result pos="117"><Field name="sourceId" type="string">446138</Field><Field name="corporatePublicationTitle" type="string">Annual Report 2001: Ono Pharmaceutical Co Ltd - Dedicated to Man's fight against disease and pain</Field><Field name="corporatePublicationType" type="string">Annual Report</Field><Field name="corporatePublicationDatePublication" type="datetime">2001-06-28T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Ono Pharmaceutical Co Ltd</Field></Result><Result pos="118"><Field name="sourceId" type="string">399819</Field><Field name="corporatePublicationTitle" type="string">Annual report: chairman's statement. Analgesia: Devacade and Colycade - for enhancing the pain relief produced by morphine</Field><Field name="corporatePublicationType" type="string">Company World Wide Web site</Field><Field name="corporatePublicationDatePublication" type="datetime">2001-02-23T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">ML Laboratories plc</Field></Result><Result pos="119"><Field name="sourceId" type="string">241305</Field><Field name="corporatePublicationTitle" type="string">Drug development pipeline: Dopamine D1 agonists, CeNeS, Alzheimers therapeutics, CeNeS, pain therapeutics, CeNeS/Kings College</Field><Field name="corporatePublicationType" type="string">Company Communication</Field><Field name="corporatePublicationDatePublication" type="datetime">1997-04-04T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">CeNeS Limited</Field></Result><Result pos="120"><Field name="sourceId" type="string">1209320</Field><Field name="corporatePublicationTitle" type="string">PF0713 Produced Rapid Induction of General Anesthesia without Injection Pain in a Phase 1 Study</Field><Field name="corporatePublicationType" type="string">Company Presentation</Field><Field name="corporatePublicationDatePublication" type="datetime">2009-10-21T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">PharmacoFore Inc</Field></Result><Result pos="121"><Field name="sourceId" type="string">1148298</Field><Field name="corporatePublicationTitle" type="string">To provide patients with therapeutics that address today’s unmet medical needs in pain and inflammation</Field><Field name="corporatePublicationType" type="string">Company Publication</Field><Field name="corporatePublicationDatePublication" type="datetime">2009-05-31T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Cerimon Pharmaceuticals Inc</Field></Result><Result pos="122"><Field name="sourceId" type="string">1421605</Field><Field name="corporatePublicationTitle" type="string">FDA Orphan Drug Designations and Approvals: zoledronic acid; Treatment of complex regional pain syndrome (CRPS)</Field><Field name="corporatePublicationType" type="string">Company World Wide Web site</Field><Field name="corporatePublicationDatePublication" type="datetime">2013-05-06T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Food and Drug Administration</Field></Result><Result pos="123"><Field name="sourceId" type="string">1770451</Field><Field name="corporatePublicationTitle" type="string">FDA Orphan Drug Designations and Approvals: bupivacaine hydrochloride; treatment of pain associated with postherpetic neuralgia</Field><Field name="corporatePublicationType" type="string">Company World Wide Web site</Field><Field name="corporatePublicationDatePublication" type="datetime">2016-05-31T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Food and Drug Administration</Field></Result><Result pos="124"><Field name="sourceId" type="string">1139094</Field><Field name="corporatePublicationTitle" type="string">ARRY-797, a Small Molecule p38? Inhibitor, Has a Good Safety Profile and Provides Pain Relief in Clinical Studies</Field><Field name="corporatePublicationType" type="string">Company Publication</Field><Field name="corporatePublicationDatePublication" type="datetime">2010-08-31T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Array BioPharma Inc</Field></Result><Result pos="125"><Field name="sourceId" type="string">1102174</Field><Field name="corporatePublicationTitle" type="string">Society for Ambulatory Anesthesia Annual Meeting: Intranasal Ketorolac (ROX-888) for Postoperative Pain: A Phase 3, Double-Blind, Randomized Study</Field><Field name="corporatePublicationType" type="string">Company World Wide Web site</Field><Field name="corporatePublicationDatePublication" type="datetime">2008-12-31T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Singla N, Singla S, Minkowitz H, Brown C, Moodie J</Field></Result><Result pos="126"><Field name="sourceId" type="string">1543089</Field><Field name="corporatePublicationTitle" type="string">A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi Center Trial of Pregabalin Versus Placebo in the Treatment of Neuropathic Pain Associated with HIV Neuropathy</Field><Field name="corporatePublicationType" type="string">Company Publication</Field><Field name="corporatePublicationDatePublication" type="datetime">2008-12-31T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string"></Field></Result><Result pos="127"><Field name="sourceId" type="string">1895559</Field><Field name="corporatePublicationTitle" type="string">AnestaGel–P Provides Greater Analgesia in a Rat Model of PostOperative Incisional Pain with Mechanical Allodynia than Exparel at 24 and 48 Hours</Field><Field name="corporatePublicationType" type="string">Company Publication</Field><Field name="corporatePublicationDatePublication" type="datetime">2016-06-29T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Taylor W, Sipple DP, Sinicropi SM</Field></Result><Result pos="128"><Field name="sourceId" type="string">1530910</Field><Field name="corporatePublicationTitle" type="string">Flexion: New Paradigms for the Treatment of Pain - Presentation at the Cowen and Company 2014 Annual Health Care Conference</Field><Field name="corporatePublicationType" type="string">Company Presentation</Field><Field name="corporatePublicationDatePublication" type="datetime">2014-03-03T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Flexion Therapeutics</Field></Result><Result pos="129"><Field name="sourceId" type="string">2020459</Field><Field name="corporatePublicationTitle" type="string">Phase 2 Studies of HTX-011 in the Management of Post-Operative Pain - Positive Top -Line Results across Bunion and Hernia Studies</Field><Field name="corporatePublicationType" type="string">Company Presentation</Field><Field name="corporatePublicationDatePublication" type="datetime">2016-08-01T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Heron Therapeutics Inc</Field></Result><Result pos="130"><Field name="sourceId" type="string">1365878</Field><Field name="corporatePublicationTitle" type="string">PHE377: A novel clinical-stage TRPV1 antagonist devoid of “class” side effects for the treatment of chronic pain syndromes</Field><Field name="corporatePublicationType" type="string">Company Publication</Field><Field name="corporatePublicationDatePublication" type="datetime">2013-02-05T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">PharmEste SRL</Field></Result><Result pos="131"><Field name="sourceId" type="string">1104282</Field><Field name="corporatePublicationTitle" type="string">Society for Biological Sciences Conference: Identification of Novel Selective CB2 Agonists for Pain Treatment through an HTS Campaign with chAMPion Technology</Field><Field name="corporatePublicationType" type="string">Company Presentation</Field><Field name="corporatePublicationDatePublication" type="datetime">2010-12-31T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Axxam SpA</Field></Result><Result pos="132"><Field name="sourceId" type="string">290425</Field><Field name="corporatePublicationTitle" type="string">Drug development pipeline: Parkinsons therapeutics, CeNeS/Kings College, Alzheimers therapeutics, CeNeS, CEE-04-421, pain therapeutics, CeNeS/Kings College</Field><Field name="corporatePublicationType" type="string">Company Communication</Field><Field name="corporatePublicationDatePublication" type="datetime">1998-10-07T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">CeNeS Ltd</Field></Result><Result pos="133"><Field name="sourceId" type="string">1724369</Field><Field name="corporatePublicationTitle" type="string">Depomed Inc Corporate Call to Acquires U.S. Rights to Late-Stage, First-in-Class Pain Product from Grunenthal</Field><Field name="corporatePublicationType" type="string">Company Presentation</Field><Field name="corporatePublicationDatePublication" type="datetime">2015-11-17T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Depomed Inc</Field></Result><Result pos="134"><Field name="sourceId" type="string">1142479</Field><Field name="corporatePublicationTitle" type="string">Azur Pharma Announces the Closing of the Acquisition of PRIALT CNS/Pain Specialty Infrastructure - - - End-User Sales of $20 Million in 2009</Field><Field name="corporatePublicationType" type="string">Company World Wide Web site</Field><Field name="corporatePublicationDatePublication" type="datetime">2010-05-10T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Azur Pharma</Field></Result><Result pos="135"><Field name="sourceId" type="string">1652817</Field><Field name="corporatePublicationTitle" type="string">FDA Orphan Drug Designations and Approvals: zoledronate D,L-lysine monohydrate (ZLM); Treatment of complex regional pain syndrome (CRPS)</Field><Field name="corporatePublicationType" type="string">Company World Wide Web site</Field><Field name="corporatePublicationDatePublication" type="datetime">2015-04-21T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Food and Drug Administration</Field></Result><Result pos="136"><Field name="sourceId" type="string">693128</Field><Field name="corporatePublicationTitle" type="string">Ono Pharmaceutical Co Ltd: Annual report 2006 "Dedicated to Man's Fight against Disease and Pain" Year ended March 31, 2006</Field><Field name="corporatePublicationType" type="string">Annual Report</Field><Field name="corporatePublicationDatePublication" type="datetime">2006-06-29T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Ono Pharmaceutical Co Ltd</Field></Result><Result pos="137"><Field name="sourceId" type="string">1574744</Field><Field name="corporatePublicationTitle" type="string">A single-blind two-part study to rechallenge with subcutaneous GR43175C, patients who had previously experienced an adverse event involving discomfort or pain in the chest following GR43175C administration</Field><Field name="corporatePublicationType" type="string">Company Publication</Field><Field name="corporatePublicationDatePublication" type="datetime">2014-12-31T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string"></Field></Result><Result pos="138"><Field name="sourceId" type="string">990738</Field><Field name="corporatePublicationTitle" type="string">A3471107: A multicenter, open label trial to evaluate analgesic effect of intravenous and subsequent oral therapy with parecoxib/valdecoxib (Bextra IM/IV - Bextra) 40 mg for treatment of post laparoscopic surgery pain</Field><Field name="corporatePublicationType" type="string">Company Publication</Field><Field name="corporatePublicationDatePublication" type="datetime">2008-04-01T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Pfizer Inc</Field></Result><Result pos="139"><Field name="sourceId" type="string">1574982</Field><Field name="corporatePublicationTitle" type="string">A Multicenter, randomized, double-blind, parallel-group study examining the effect of fluticasone propionate aqueous nasal spray 200mcg QD in subjects with sinus pain and pressure associated with nasal congestion due to allergic rhinitis</Field><Field name="corporatePublicationType" type="string">Company Publication</Field><Field name="corporatePublicationDatePublication" type="datetime">2014-12-31T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string"></Field></Result><Result pos="140"><Field name="sourceId" type="string">292920</Field><Field name="corporatePublicationTitle" type="string">Drug development pipeline: ASP-05, gene therapy (schizophrenia), gene therapy (pain), gene therapy (cancer), BAY-44-3428, gene discovery (asthma), human growth hormone mimics, Factor Xa inhibitors</Field><Field name="corporatePublicationType" type="string">Company Communication</Field><Field name="corporatePublicationDatePublication" type="datetime">1998-07-30T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Axys Pharmaceuticals Inc</Field></Result></PagedResults><DatasetCounts></DatasetCounts><HitTerms><Terms><Term>pain</Term></Terms></HitTerms></ns2:com.thomson.ls.soa.stack.soaservices.service.contract.soap.v4.search.SearchOutput>